Problems in the treatment of Parkinsonism.
D000978:Antiparkinson Agents / Q000009:adverse effects; D001161:Arteriosclerosis / Q000150:complications; D002230:Carbidopa / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004338:Drug Combinations; D005132:Eye Manifestations; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D001523:Mental Disorders / Q000209:etiology; D009069:Movement Disorders / Q000175:diagnosis; D010276:Parasympatholytics / Q000627:therapeutic use; D010292:Paresthesia / Q000209:etiology; D010300:Parkinson Disease / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D014786:Vision Disorders / Q000209:etiology
D000978:Antiparkinson Agents; D004338:Drug Combinations; D010276:Parasympatholytics; D007980:Levodopa; D002230:Carbidopa